LabCorp Announces the Availability of Expanded Services for Inflammatory
BURLINGTON, N.C. -- April 1, 2013
Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) announced
today the availability of an expanded testing menu to help clinicians
diagnose, treat and monitor the course of Inflammatory Bowel Disease (IBD).
Gastrointestinal (GI) tract disorders are often presented with non-specific
symptoms and are difficult to diagnose, especially in primary care settings.
Inflammatory Bowel Disease (IBD) is one of the most common and serious
gastrointestinal disorders. The two clinically distinctive forms of IBD are
ulcerative colitis and Crohn's disease. Treatments can also be complicated,
involving immunosuppressant therapies, biological drugs and/or surgery.
In support of improving IBD diagnosis and treatment, LabCorp has launched an
expanded IBD testing profile that helps to identify IBD patients and
differentiate between ulcerative colitis and Crohn’s disease. The IBD Expanded
Profile includes ulcerative colitis and Crohn’s disease-specific antibody
markers that improve diagnostic sensitivity and provide valuable prognostic
information regarding the severity of disease. For patients diagnosed with
IBD, LabCorp’s TPMT Enzyme Activity assay can be utilized prior to thiopurine
drug treatment to assess dosing levels and potential adverse drug reaction.
Once a patient has started thiopurine treatment, physicians can use the
thiopurine Metabolites test to help optimize ongoing dosing to reach and
maintain therapeutic goals and avoid possible drug toxicity. LabCorp also
offers testing for patients treated with new biological drugs like infliximab
that allow physicians to monitor drug concentration levels and assess the
impact of anti-infliximab antibody levels on drug efficacy.
“GI disorders are difficult to diagnose,” said Dr. Mark Brecher, LabCorp’s
Chief Medical Officer. “The IBD Expanded Profile helps to diagnose disease and
contributes to optimizing treatment.”
These enhancements to LabCorp’s IBD test menu are adjuncts to its broader
offering of digestive disease testing that includes cost-efficient cascade
testing to help physicians diagnose Irritable Bowel Syndrome and non-Celiac
Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its Specialty Testing Group:
The Center for Molecular Biology and Pathology, National Genetics Institute,
ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink
Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc,
Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox,
and Endocrine Sciences. LabCorp conducts clinical trials testing through its
LabCorp Clinical Trials division. LabCorp clients include physicians,
government agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our company, visit our Web site
This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2012, and subsequent SEC filings.
Laboratory Corporation of America^® Holdings
Stephen Anderson, 336-436-5076
Press spacebar to pause and continue. Press esc to stop.